达雷妥尤单抗在经重度预治疗的AL淀粉样变性患者中产生快速且深度的血液学缓解
该回顾性研究纳入25例既往接受过治疗的免疫球蛋白轻链(AL)淀粉样变性患者,接受达雷妥尤单抗16 mg/kg每周1次共8周,随后每2周1次共8剂,之后每4周1次。总体血液学缓解率为76%,其中完全缓解(CR)36%、非常好的部分缓解(VGPR)24%,中位起效时间1个月,治疗耐受性良好。
要点
- 达雷妥尤单抗在重度预治疗的AL淀粉样变性患者中总体血液学缓解率达76%。
- 达雷妥尤单抗治疗后CR率为36%,VGPR率为24%,中位起效时间1个月。
- 即使72%患者有心脏AL受累,治疗仍耐受良好,仅见1-2级输注反应,无3-4级反应。
核心结论
- 达雷妥尤单抗是一种高效药物,在本队列的重度预治疗AL淀粉样变性患者中产生了快速且深度的血液学缓解,且无意外毒性。
研究设计与样本
- 回顾性研究,纳入25例连续既往接受过治疗的AL淀粉样变性患者,接受达雷妥尤单抗治疗。
- 达雷妥尤单抗给药方案为16 mg/kg每周1次共8周,随后每2周1次共8剂,之后每4周1次。
- 患者既往接受中位3线治疗,仅5例曾达到血液学完全缓解(CR)。
主要发现
- 总体血液学缓解率为76%,包括CR 36%和非常好的部分缓解(VGPR)24%。
- 中位起效时间为1个月。
- 72%的患者有心脏AL受累,治疗仍耐受良好。
- 15例患者发生1-2级输注反应,未观察到3级或4级反应。
关键数值与推荐
- 总体血液学缓解率76%,CR率36%,VGPR率24%。
- 中位起效时间1个月。
- 1-2级输注反应发生于15例患者,无3级或4级反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The majority of patients with immunoglobulin light chain amyloidosis (AL) fail to achieve a complete response (CR) to standard light chain suppressive chemotherapy, and almost all patients eventually experience hematologic relapse and progression of organ involvement. Additional well-tolerated treatment options are needed. We present our retrospective experience of 25 consecutive previously treated AL patients who received daratumumab, a CD38-directed monoclonal antibody approved for the treatment of multiple myeloma. Daratumumab was administered at 16 mg/kg weekly for 8 weeks, then every 2 weeks for 8 doses, and then every 4 weeks. Patients had received a median of 3 prior lines of therapy, with a previous hematologic CR in only 5 patients. The overall hematologic response rate to daratumumab was 76%, including CR in 36% and very good partial response in 24%. Median time to response was 1 month. Therapy was well tolerated, even among the 72% of patients with cardiac AL involvement. Grade 1-2 infusion reactions occurred in 15 patients, but no grade 3 or 4 reactions were observed. Daratumumab is a highly effective agent that produced rapid and deep hematologic responses without unexpected toxicity in our cohort of heavily pretreated AL patients.
引用
- Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017. PMID: 28615223. doi:10.1182/blood-2017-01-763599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。